IL3 주식 개요 인테그라 라이프사이언스 홀딩스는 신경외과, 신경 중환자 치료, 이비인후과에서 사용하는 수술 기구, 신경외과 제품, 상처 치료 제품을 제조 및 판매하는 회사입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Integra LifeSciences Holdings Corporation 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Integra LifeSciences Holdings 과거 주가 현재 주가 US$25.00 52주 최고치 US$41.60 52주 최저치 US$15.30 베타 1.18 1개월 변경 11.61% 3개월 변경 사항 0.81% 1년 변경 사항 -34.21% 3년 변화 -56.52% 5년 변화 -53.27% IPO 이후 변화 254.86%
최근 뉴스 및 업데이트
Integra LifeSciences Holdings Corporation to Report Q4, 2024 Results on Feb 25, 2025 Feb 04
Integra LifeSciences Launches Integra Institute for Healthcare Professionals (HCPs) Jan 15 Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Updates Earnings Guidance for the Full Year of 2024
Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.24 profit in 3Q 2023) Nov 04
Investor sentiment deteriorates as stock falls 21% Aug 05
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.052 profit in 2Q 2023) Jul 30 더 많은 업데이트 보기
Integra LifeSciences Holdings Corporation to Report Q4, 2024 Results on Feb 25, 2025 Feb 04
Integra LifeSciences Launches Integra Institute for Healthcare Professionals (HCPs) Jan 15 Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Updates Earnings Guidance for the Full Year of 2024
Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.24 profit in 3Q 2023) Nov 04
Investor sentiment deteriorates as stock falls 21% Aug 05
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.052 profit in 2Q 2023) Jul 30
Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the Third Quarter and Updates Earnings Guidance for the Full Year of 2024 Jul 30
Integra LifeSciences Holdings Corporation to Report Q2, 2024 Results on Jul 29, 2024 Jul 16
Integra LifeSciences Holdings Corporation(NasdaqGS:IART) dropped from Russell 1000 Dynamic Index Jul 03
Independent Presiding Director recently bought €917k worth of stock May 23
Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Second Quarter and Full Year 2024 May 08
New minor risk - Share price stability May 07
First quarter 2024 earnings released: US$0.042 loss per share (vs US$0.30 profit in 1Q 2023) May 06
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million. Apr 03 Integra LifeSciences Holdings Corporation to Report Q1, 2024 Results on Apr 25, 2024
Integra LifeSciences Holdings Corporation, Annual General Meeting, May 09, 2024 Mar 27
Integra Lifesciences Launches Micromatrix Flex to Provide Convenient Access to Hard-To-Reach Areas in Complex Cases Mar 12
Investor sentiment deteriorates as stock falls 19% Mar 06 Integra LifeSciences Holdings Corporation Announces Board Changes
Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the First Quarter and for the Full Year 2024 Feb 29
Full year 2023 earnings released: EPS: US$0.84 (vs US$2.18 in FY 2022) Feb 29
Integra LifeSciences Holdings Corporation to Report Q4, 2023 Results on Feb 28, 2024 Feb 08
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million. Dec 14 Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.
Third quarter 2023 earnings released: EPS: US$0.24 (vs US$0.60 in 3Q 2022) Oct 26
Levi & Korsinsky Notifies Integra Lifesciences Holdings Corporation Investors of a Class Action Lawsuit and Upcoming Deadline Oct 20
Integra LifeSciences Holdings Corporation to Report Q3, 2023 Results on Oct 25, 2023 Oct 05
Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Integra Lifesciences Holdings Corporation Sep 14
Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Integra Lifesciences Holdings Corporation Sep 13
New minor risk - Earnings quality Jul 30 Integra LifeSciences Holdings Corporation (NasdaqGS:IART) announces an Equity Buyback for $225 million worth of its shares.
Second quarter 2023 earnings released: EPS: US$0.052 (vs US$0.54 in 2Q 2022) Jul 27
Integra LifeSciences Holdings Corporation to Report Q2, 2023 Results on Jul 27, 2023 Jul 04 Integra LifeSciences Holding Corporation Announces Complete Enrollment in DuraSorb Monofilament Mesh U.S. IDE Study Jun 29
Integra Lifesciences Holdings Corporation Appoints Lea Daniels Knight as Executive Vice President, Effective June 28, 2023
President recently bought €279k worth of stock Jun 04
Now 35% undervalued after recent price drop May 24
Now 20% undervalued after recent price drop May 03
First quarter 2023 earnings released: EPS: US$0.29 (vs US$0.39 in 1Q 2022) Apr 27
Insider recently sold €95k worth of stock Mar 09
Insider recently sold €203k worth of stock Mar 01
Full year 2022 earnings released: EPS: US$2.16 (vs US$2.00 in FY 2021) Feb 23
Now 20% undervalued Feb 18 Integra LifeSciences Holdings Corporation Announces Executive Changes
Now 21% undervalued Jan 26 Integra LifeSciences Holdings Corporation Provides Revenue Guidance for Fourth Quarter 2022 and Full-Year 2022
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) completed the acquisition of Surgical Innovation Associates, Inc. Dec 07
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire Surgical Innovation Associates, Inc. for $140 million. Dec 02
Third quarter 2022 earnings released: EPS: US$0.60 (vs US$0.51 in 3Q 2021) Oct 27
Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year Oct 27
Integra LifeSciences Holdings Corporation to Report Q3, 2022 Results on Oct 26, 2022 Oct 09
Integra LifeSciences Holdings Corporation Appoints Harvinder Singh as Executive Vice President and President of Integra’s International Business Oct 07
Integra LifeSciences Holdings Corporation Announces Resignation of Glenn Coleman as Chief Operating Officer, Effective October 3, 2022 Aug 30
Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO Aug 17
Independent Director recently sold €439k worth of stock Aug 09
An unknown buyer entered into a definitive agreement to acquire Non-core Traditional Wound Care Business of Integra LifeSciences Holdings Corporation (NasdaqGS:IART) for $28.8 million. Jul 29
Second quarter 2022 earnings released: EPS: US$0.54 (vs US$0.41 in 2Q 2021) Jul 28 Integra LifeSciences Holdings Corporation Revises Financial Guidance for the Third Quarter and Full Year 2022
Integra LifeSciences Holdings Corporation Appoints Renee Lo to its Board of Directors Jul 20
Integra LifeSciences Holdings Corporation to Report Q2, 2022 Results on Jul 27, 2022 Jul 02
First quarter 2022 earnings released: EPS: US$0.39 (vs US$0.54 in 1Q 2021) Apr 28
Integra LifeSciences Holdings Corporation, Annual General Meeting, May 13, 2022 Apr 09
Integra LifeSciences Holdings Corporation to Report Q1, 2022 Results on Apr 27, 2022 Apr 02
Insider recently sold €75k worth of stock Mar 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the First Quarter and Full Year 2022 Feb 24
Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2021 Jan 12
Insider recently sold €214k worth of stock Nov 09
Third quarter 2021 earnings released: EPS US$0.51 (vs US$0.38 in 3Q 2020) Nov 03
Insider recently sold €242k worth of stock Aug 11
Second quarter 2021 earnings released: EPS US$0.41 (vs US$0.004 loss in 2Q 2020) Jul 29
Integra LifeSciences Announces Positive Clinical Outcomes for Primatrix® Dermal Repair Scaffold for the Management of Diabetic Foot Ulcers Jul 20
Independent Director recently sold €69k worth of stock Jun 08
Integra Lifesciences Holdings Corporation Reaffirms Earnings Guidance for Second Quarter and Full Year 2021 May 21
First quarter 2021 earnings released: EPS US$0.53 (vs US$0.11 in 1Q 2020) Apr 30
Integra Lifesciences Holdings Corporation Provides Revenue Guidance for the Second Quarter and Full Year 2021 Apr 29
Independent Director has left the company Mar 01
Insider recently sold €1.4m worth of stock Feb 28
Full year 2020 earnings released: EPS US$1.57 (vs US$0.59 in FY 2019) Feb 20
Revenue beats expectations Feb 20
Integra LifeSciences Holdings Corporation Announces Board Changes, Effective February 26, 2021 Feb 13
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) completed the acquisition of ACell, Inc. Jan 22
Integra LifeSciences Holdings Corporation to Report Q4, 2020 Results on Feb 18, 2021 Jan 15
New 90-day high: €55.00 Jan 14 주주 수익률 IL3 DE Medical Equipment DE 마켓 7D 0.8% -0.2% -0.2% 1Y -34.2% -4.7% 13.7%
전체 주주 수익률 보기
수익률 대 산업: IL3 지난 1년 동안 -4.7 %를 반환한 German Medical Equipment 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: IL3 지난 1년 동안 13.7 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is IL3's price volatile compared to industry and market? IL3 volatility IL3 Average Weekly Movement 5.9% Medical Equipment Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.1% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: IL3 지난 3개월 동안 German 시장에 비해 상당한 가격 변동성이 발생하지 않았습니다.
시간에 따른 변동성: IL3 의 주간 변동성 ( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 인테그라 라이프사이언스 홀딩스는 신경외과, 신경 중환자 치료, 이비인후과에서 사용되는 수술 기구, 신경외과 제품, 상처 치료 제품을 제조 및 판매합니다. 이 회사는 Codman 특수 수술 및 조직 기술의 두 가지 부문으로 운영됩니다. 조직 절제 장비, 경막 복구 제품, 뇌척수액 관리 장치, 두개 내 모니터링 장비, 두개골 안정화 장비 등 신경외과 및 신경 중환자 치료 제품과 수술용 헤드램프 및 계측기, 애프터마켓 서비스를 제공합니다.
자세히 보기 Integra LifeSciences Holdings Corporation 기본 사항 요약 Integra LifeSciences Holdings 의 수익과 매출은 시가총액과 어떻게 비교하나요? IL3 기본 통계 시가총액 €1.93b 수익(TTM ) -€6.29m 수익(TTM ) €1.50b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) IL3 손익 계산서(TTM ) 수익 US$1.56b 수익 비용 US$632.40m 총 이익 US$932.52m 기타 비용 US$939.06m 수익 -US$6.54m
주당 순이익(EPS) -0.085 총 마진 59.59% 순이익 마진 -0.42% 부채/자본 비율 118.9%
IL3 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/02/05 09:11 장 마감 주가 2025/02/05 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기 .
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.
애널리스트 출처 Integra LifeSciences Holdings Corporation 30 애널리스트 중 11 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 David Toung Argus Research Company Matthew Taylor Barclays Charley Jones Barrington Research Associates, Inc.
27 더 많은 분석가 보기 
